Literature DB >> 12088953

Small-dose ketamine improves the postoperative state of depressed patients.

Akira Kudoh1, Yoko Takahira, Hiroshi Katagai, Tomoko Takazawa.   

Abstract

UNLABELLED: We investigated whether ketamine is suitable for depressed patients who had undergone orthopedic surgery. We studied 70 patients with major depression and 25 patients as the control (Group C). The depressed patients were divided randomly into two groups; patients in Group A (n = 35) were induced with propofol, fentanyl, and ketamine and patients in Group B (n = 35) were induced with propofol and fentanyl, and all patients were maintained with 1.5%-2.0% isoflurane plus nitrous oxide. The mean Hamilton Depression Rating (HDR) score was 12.7 +/- 5.4 for Group A and 12.3 +/- 6.0 for Group B 2 days before surgery and 9.9 +/- 4.1 for Group A and 14.4 +/- 3.8 for Group B 1 day after surgery. The HDR score in Group A 1 day after surgery was significantly (P < 0.05) lower than that in Group B. The HDR score in Group C was 4.2 +/- 1.7 2 days before surgery and 4.8 +/- 1.6 1 day after surgery. Depressed mood, suicidal tendencies, somatic anxiety, and hypochondriasis significantly decreased in Group A as compared with Group B. Postoperative pain scores in Group A at 8 and 16 h after the end of anesthesia were 26.6 +/- 8.7 and 24.9 +/- 8.2, respectively, which were significantly (P < 0.05) lower than 34.3 +/- 12.0 and 31.1 +/- 8.8 in Group B. In conclusion, small-dose ketamine improved the postoperative depressive state and relieved postoperative pain in depressed patients. IMPLICATIONS: NMDA receptor antagonists are reported to be effective for improving depression. It remains unclear whether ketamine, which is an NMDA receptor antagonist, postoperatively affects the psychological state in depressed patients. We investigated the effect of 1.0 mg/kg of ketamine on postoperative outcomes in depressed patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088953     DOI: 10.1097/00000539-200207000-00020

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  46 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

3.  Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

Authors:  Scott A Irwin; Alana Iglewicz; Richard A Nelesen; Jessica Y Lo; Connie H Carr; Sheilani D Romero; Linda S Lloyd
Journal:  J Palliat Med       Date:  2013-06-27       Impact factor: 2.947

4.  A comment on Fond and colleagues' systematic review and meta-analysis of ketamine in the treatment of depressive disorders (Psychopharmacology 2014; Jul 20 [Epub ahead of print]).

Authors:  Alexander McGirr; Marcelo T Berlim
Journal:  Psychopharmacology (Berl)       Date:  2014-09-02       Impact factor: 4.530

5.  Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.

Authors:  Michael F Grunebaum; Hanga C Galfalvy; Tse-Hwei Choo; John G Keilp; Vivek K Moitra; Michelle S Parris; Julia E Marver; Ainsley K Burke; Matthew S Milak; M Elizabeth Sublette; Maria A Oquendo; J John Mann
Journal:  Am J Psychiatry       Date:  2017-12-05       Impact factor: 18.112

6.  Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.

Authors:  Chadi G Abdallah; Madonna Fasula; Ben Kelmendi; Gerard Sanacora; Robert Ostroff
Journal:  J ECT       Date:  2012-09       Impact factor: 3.635

Review 7.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Fluoxetine partly exerts its actions through GABA: a neurochemical evidence.

Authors:  M Zafer Gören; Esra Küçükibrahimoglu; Kemal Berkman; Berna Terzioglu
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

9.  Effect of Ketamine, Thiopental and Ketamine-Thiopental Combination during Electroconvulsive Therapy for Depression.

Authors:  Özlem Özkan Kuşçu; Feride Karacaer; Ebru Biricik; Ersel Güleç; Lut Tamam; Yasemin Güneş
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-08-21

10.  Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains.

Authors:  Chalon R Majewski-Tiedeken; Cara R Rabin; Steven J Siegel
Journal:  Drug Alcohol Depend       Date:  2007-10-24       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.